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PathophysiologyRare bone diseases account for 5% of all birth defects and can cause signiﬁcant morbidity throughout patients'
lives. Signiﬁcant progress is being made to elucidate the pathophysiological mechanisms underlying these
diseases. This paper summarizes presentation highlights of aworkshop on Rare Skeletal Diseases convened to ex-
plore how the study of rare diseases has inﬂuenced the ﬁeld's understanding of bone anabolism and catabolism
and directed the search for new therapies beneﬁting patients with rare conditions as well as patients with
common skeletal disorders.
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different components of bone—cells, vasculature, and matrix—makes it
challenging to dissect the biological mechanisms affected by these
rare disorders. Newmethods for imaging the skeleton, performingmas-
sively parallel sequencing of DNA and RNA, creating animal models of
human skeletal disease, and studying the consequences of mutation at
the single cell level, have facilitated our understanding of fundamental
mechanisms responsible for skeletal growth and homeostasis. Many
new discoveries that are relevant to persons affected by common skel-
etal disorders such as osteoporosis and osteoarthritis have their origins
in the study of patients with rare bone diseases. Thus, studying rare
skeletal diseases has improved our understanding of skeletal biology
and contributed to the development of new approaches for improving
bone health.
This manuscript summarizes twelve lectures delivered by invited
speakers at an NIH-supported workshop on Rare Bone Diseases held
on September 11, 2014, in Houston, TX, and attended by more than
250 clinicians and scientists.
The nosology of rare bone diseases — Krakow
Dr. Deborah Krakow provided examples of clinical, radiologic, and
biochemical characterizations of rare skeletal diseases facilitating the
discovery of pathways and processes involved in skeletal patterning,
growth, and homeostasis.
Heritable skeletal disorders form a heterogeneous group of more
than 450 well-deﬁned diseases, resultant from mutations in more
than 200 genes. Initial attempts at classiﬁcation relied primarily on
radiographic and clinical ﬁndings and distinguished between skeletal
dysplasias, a general condition affecting bone and cartilage, and
dysostoses, a disorder manifested by abnormalities in an individual or
group of bones [2]. Despite variability in the clinical manifestations
and severity of these pathological states, signiﬁcant phenotypic overlap
posed a challenge in disease recognition and risk assessment, creating
the need for a comprehensive, systematic classiﬁcation that could
guide diagnosis.
Spranger ﬁrst proposed the concept of ‘bone families’ in the 1980s as
disorders with common phenotypic, radiographic, and histologic
features sharing the same underlying pathophysiological mechanisms
and/or molecular pathways [3]. With the advent of molecular biology,
diseases once thought to be distinct entities are now grouped according
to the gene(s) and pathway(s) affected. For example, mutations
in ﬁlamin A account for conditions displaying wide variability such
as Melnick–Needles syndrome, otopalatodigital syndromes and
frontometaphyseal dysplasia [2]. By contrast, similar clinical features
may be due tomutations in different genes, as in the case of themultiple
epiphyseal dysplasia group of diseases, associated with defects in carti-
lage oligomeric matrix protein, collagen type IX, and matrilin 3, all
thought to similarly participate in the assembly of the extracellular ma-
trix (ECM) [2]. Polygenic disease entities may in fact share the same
mechanistic basis. Osteogenesis imperfecta (OI), for instance, is attribut-
ed to the action of several dysfunctional proteins, previously deemed
unrelated and now recognized to be involved in common processes in
mineralization and signaling in the matrix. The study of OI has allowed
biologists to identify interactions between gene products that would
have never been predicted. Further, new pathological components
have been identiﬁed as a result of recognizing that a gene associated
with a speciﬁc bone disorder is also responsible for symptoms affecting
other organs and systems. Gain-of-function mutations in transient
receptor potential cation channel subfamily Vmember 4 (TRPV4), a cal-
cium channel, result in distinctive phenotypes: mild brachyolmia,
spondylometaphyseal dysplasia, Kozlowski type, and the more severe
metatropic dysplasia [2]. Notably, Charcot–Marie–Tooth disease type
2C is also caused by defects in this receptor [4], an observation that
led to the identiﬁcation of a pathological neuromuscular component
in the TRPV4 family of disorders [5].Themost recent revision of theNosology and Classiﬁcation of Genet-
ic Skeletal Disorders combines pathological, histologic, and biochemical
information, as well as molecular and developmental aspects, to
categorize recognized disease entities into 40 distinct groups [2].
The disease classiﬁcation scheme goes beyond its role in assisting diag-
nosis and informing treatment and counseling, by suggesting links be-
tween molecules and pathways. Serpentine ﬁbula-polycystic kidney
syndrome, thought to be a ﬁlamin-related disorder based on clinical
and radiographic phenotype, clearly illustrates this concept. However
serpentine ﬁbula-polycystic kidney syndrome and the rare Hajdu–Che-
ney syndrome are caused by truncating mutations in neurogenic locus
notch homolog 2 (NOTCH2) [6]. This raises the interesting hypothesis
of ﬁlamin involvement in the NOTCH signaling pathway.
The classiﬁcation of rare bone diseases has undoubtedly delineated
important elements of normal and diseased bone physiology and con-
tributed to improved diagnosis. In the age of molecular medicine, and
despite some unsolved entities, nosological schemes enable clinicians
to quickly recognize signs and symptoms, establish otherwise unfore-
seen mechanistic relationships, and potentially identify new therapeu-
tic targets.
Skeletal elements affected in rare bone disorders
Drs. Lynda Bonewald, Stuart Ralston, Maurizio Paciﬁci, Bjorn Olsen,
and Brendan Lee gave examples of rare bone diseases yielding insights
about independent and coordinated functions of bone cells, vasculature,
and matrix on skeletal health.
Osteoblasts and osteocytes — Bonewald
Osteoblasts have a vital role in bone homeostasis and undergo a
tightly regulated differentiation process. Runt-related transcription
factor 2 (RUNX2) is an early mediator of osteoblast speciﬁcation and di-
rect regulator of OSTERIX (OSX), a member of the Sp zinc-ﬁnger tran-
scription factor family that further speciﬁes the osteoblastic lineage
[7]. Deﬁciencies in osteoblast-speciﬁc proteins such as type I collagen
and tissue non-speciﬁc alkaline phosphatase (TNSALP) have been asso-
ciated with OI and hypophosphatasia, respectively [2]. Osteocytes,
which constitute over 95% of all bone cells in the adult skeleton, origi-
nate from the terminal differentiation of osteoid-producing osteoblasts
that become embedded in the bone matrix. They have endocrine and
mechanosensory functions in bone remodeling and are able to establish
and direct communication between themselves and the bone surface by
extending and retracting their cellular processes into the bone marrow
and vascular spaces. Osteocytes also regulate osteoclasts through recep-
tor activator of nuclear factor kappa-B (NFκB) ligand (RANKL) and
produce osteoblast-modulating factors such as sclerostin, encoded by
the sclerostin gene (SOST) [8]. Deleterious mutations in SOST, a strong
inhibitor of bone formation responsive to mechanical load via the
wingless-related integration site (Wnt)/β-catenin signaling pathway,
result in sclerosing bone syndromes,whereas activatingmutations in ﬁ-
broblast growth factor 23 (FGF23), also highly expressed in osteocytes,
cause autosomal dominant hypophosphatemic rickets [2]. Autosomal
recessive hypophosphatemic rickets is due to defects in dentin matrix
acidic phosphoprotein 1 (DMP1), and a sex-linked form of the disease
is caused by mutations in phosphate-regulating neutral endopeptidase
on chromosome X (PHEX) [9]. DMP1 and PHEX downregulate FGF23
signaling, which is actively involved in the systemic regulation of phos-
phate metabolism, essential for bone mineralization [10]. Elevated
levels of circulating FGF23 also exert pathological effects in the heart
by inducing vascular calciﬁcation in patients with chronic kidney
disease [11].
Although therapeutic approaches to bone disease have traditionally
focused on osteoblasts, current research supports the use of agents
targeting osteocyte-speciﬁc proteins such as sclerostin. Anti-sclerostin
antibodies reduce bone loss and promote fracture healing in animal
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blosozumab are currently undergoing clinical evaluation in the context
of osteoporosis [12]. Likewise, treatment with an antibody targeting
FGF23 restores serum phosphate levels and bone defects in mice and
patients with X-linked hypophosphatemic rickets [12,13]. Finally,
denosumab, an inhibitor of RANKL, greatly reduces the risk of fractures
in post-menopausal womenwith osteoporosis through inhibition of os-
teoclast differentiation [14]. Data from this and other phase III studies
supported the marketing authorization of the agent for the treatment
of osteoporosis.
While many aspects of the important conversion of osteoblasts into
osteocytes remain unknown, including the putative role of mineraliza-
tion and the action of Wnt/β-catenin signaling in triggering this transi-
tion, future research studies addressing these questions will certainly
reveal newosteoblastic and osteocytic therapeutic targets in the context
of bone diseases.Osteoclasts — Ralston
The study of hereditary rare bonediseases has contributed to the un-
derstanding of the osteoblastic lineage, but also of monocyte-derived
osteoclasts, known to be involved in disease states affecting bone
mass. Oligogenic Paget's disease of bone (PDB), the result of increased
osteoclastic activity or number, is characterized by osteolytic lesions
with high bone turnover, pain and fractures, whereas in osteopetrosis
impaired differentiation and function of the bone-resorptive cells result
in increased bonemass associated with bonemarrow failure, patholog-
ical fractures, osteoarthritis, and osteomyelitis. Osteoclast-rich and
-poor osteopetrosis subtypes present distinct genetic causes. Loss-of-
function mutations in the RANKL/RANK system deplete the osteoclastic
cellular reserves, and deﬁciencies in carbonic anhydrase and in bone-
matrix-degrading protein cathepsin K hamper osteoclast function [15].
Not surprisingly, odanacatib, an inhibitor of cathepsin K, induced
impressive improvements in bonemass density in phase III clinical trials
[16]. Likewise, predisposing genes for PDB are involved in important
osteoclastic processes and constitute feasible therapeutic targets. In
opposition to what occurs in osteopetrosis, gain-of-function mutations
in RANK explain the clinical manifestation in PDB-like syndromes such
as familial expansile osteolysis and early-onset PDB, whereas loss-of-
function mutations in osteoprotegerin (OPG), an inhibitor of osteoclas-
togenesis, underlie the pathological features of juvenile PDB. Classical
PDB, by contrast, may result from alterations in genes coding formacro-
phage colony-stimulating factor 1 [17], which promotes osteoclast dif-
ferentiation from mesenchymal stem cells, and p62, a protein involved
in RANKL/NFκB signaling [18]. New genes identiﬁed by genome-wide
association studies include those coding for optineurin [17], a negative
regulator of osteoclast differentiation, and for Ras and Rab interactor
3,with unknown function. Based on past ﬁndings, it is not unreasonable
to expect that these new factors may constitute relevant targets in the
treatment of bone diseases, but the role of the products of these genes
transcends therapeutic intervention. The Zoledronate In the Prevention
of Paget's disease (ZIPP) study (ISRCTN11616770) is currently testing
the use of genetic markers to target treatment. Individuals with a family
history of PDB are screened for mutations in SQSTM1, the gene coding
for p62, and are subsequently randomized to receive zoledronic acid
or placebo and evaluated for bone lesions for ﬁve years. This approach
aims to identify undiagnosed, asymptomatic participants who may
beneﬁt from early treatment in order to reduce the risk of irreversible
complications associated with the disease.
The knowledge acquired from the study of diseases associated with
osteoclast dysfunction has greatly improved our understanding of nor-
mal osteoclast biology. The continuing dissection of their molecular
mechanisms enables the identiﬁcation of therapeutic targets and poten-
tially of genetic markers that can be used to inform patient treatment
plans.Chondrocytes — Paciﬁci
Most skeletal elements, including long bones, vertebrae and cranial
base, are endochondral structures and thus chondrocytes are key
players in their embryonic formation and postnatal growth and repair.
Chondrocytes originate from condensed preskeletogenic mesenchymal
cells, and quickly organize in the growth plate where they undergo
proliferation and hypertrophy and are largely replaced by bone and
marrow cells. Several transcription factors and signaling pathways,
such as sex-determining region Y-box 9, 5 and 6 (SOX9, SOX5 and
SOX6) and RUNX2 and ﬁbroblast growth factor (FGF), Bonemorphoge-
netic protein (BMP) and WNT signaling proteins, are involved in this
intricate process which, when disrupted, leads to aberrant growth
plate development and function [19]. Rare skeletal disorders have pro-
vided critical clues into the functioning of growth plate chondrocytes,
and following are two important examples.
Hereditary multiple exostoses (HME) syndrome, characterized by
the formation of benign cartilage tumors (exostoses), illustrates the
detrimental impact of growth plate disruption. In 2–3% of the cases, ex-
ostoses may lead to chondrosarcoma, a particularly aggressive bone
cancer with poor prognosis. Interestingly, exostoses always form next
to, but never within, the growth plate, unlike other types of benign
cartilage tumors such as endochondromas. Most HME cases are caused
by a deﬁciency in glycosyl synthases exostosin (EXT) 1 and EXT2,which
results in systemic deﬁciency in heparan sulfate (HS) [20]. HS, a compo-
nent of cell-surface and matrix-associated proteoglycans, binds and
stores regulatory factors such as FGFs, WNTs, BMPs, and vascular endo-
thelial growth factor (VEGF), and regulates their distribution and activ-
ity in the growth plate [21], thusmaintaining the integrity of the growth
plate itself as well as of the growth plate–perichondrial border. Func-
tional defects in this important border result in exostosis formation.
Also, ectopic activation of prochondrogenic BMP signaling along the
perichondrium occurs prior to exostosis formation, as observed in a
perichondrium-speciﬁc Ext1 knockoutmouse [22]. Moreover, inhibition
of HS synthesis and function in vitro with heparanase or the small
molecule Surfen stimulates chondrogenesis and is accompanied by in-
creased SMAD phosphorylation and BMP receptor (BMPR) expression.
Indeed, cells obtained from patients with HME show higher levels of
heparanase, suggesting that the inhibition of this endoglycosidase
in vivo may represent a therapeutic strategy to prevent the formation
of exostoses [23].
In disorders affecting the autopod skeleton, inactivating mutations
in growth differentiation factor 5 (GDF5), amember of the transforming
growth factor-beta (TGF-β) superfamily, have recently been identiﬁed
in patients with speciﬁc forms of brachydactyly, and active forms of
the protein causemultiple synostoses syndrome 2 [2]. A uniquemutant
form of GDF5 harboring a tryptophan-to-arginine change in amino acid
414 (W414R) found in a family has recently been shown to possess con-
current gain- and loss-of-function properties; it is resistant toNoggin—a
natural antagonist of GDF5—and hence more active, but it also has re-
duced capacity to activate BMPR1A [24]. The gain-of-function property
likely caused multiple synostoses traits in the patients, while the loss-
of-function led to brachydactyly. GDF5 is thus a key determinant of
the shape, size and growth of skeletal elements directly or indirectly
affecting growth plate activity, and the multiple joint fusions observed
in patients with multiple synostoses syndrome also likely reﬂect a fail-
ure to maintain the functionality of tissue–tissue borders in mutant
skeletal elements.
The above examples reiterate the fact that the activity of the growth
plate determines the pace and extent of overall skeletal growth and
skeletalmorphogenesis, and research focusing on rare conditions affect-
ing its function has provided critical insights on skeletal development
and growth and synovial joint formation. How complex signaling net-
works maintain the integrity and functionality of tissue–tissue borders
in the skeletal system remains, however, one of the most intriguing
mysteries in skeletal biology.
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Osteoblast differentiation is closely connected to vascular develop-
ment. During early bone formation, osteoblast progenitor cells in the
perichondrium migrate into primary ossiﬁcation centers and respond
to VEGF signaling originated in hypertrophic chondrocytes. VEGF is
also produced by bone progenitor cells and osteoblasts to stimulate
perichondrial angiogenesis and osteoblast differentiation. A third
participant in this signaling network, the endothelium, stimulates oste-
oblast activity and VEGF secretion through hypoxia-inducible factor 1
alpha (HIF1α) [25,26]. It is not surprising then that abnormalities in
angiogenesis can cause signiﬁcant skeletal malformations. In fact,
germline inactivating mutations in phosphatase and tensin homolog
(PTEN) in Cowden syndrome and Bannayan–Riley–Ruvalcaba
syndrome manifest as hamartomatous growths [27], which may be in
fact an indirect effect of vascular disfunction or a direct effect of bone
disfunction. A direct effect on bone cells in humans is supported by
the presence of increased numbers of osteoblasts and bone progenitors
in a conditional Pten null mouse [28].
In Klippel–Trenaunay syndrome, vessel defects go hand in hand
with bone hypertrophy. Mutations in phosphatidylinositol 4,5-
bisphosphatase 3-kinase catalytic subunit alpha (PIK3CA) have been
identiﬁed in most of these patients, as well as in patients with congen-
ital, lipomatous, overgrowth, vascular malformations, epidermal nevi
and spinal/skeletal anomalies and/or scoliosis (CLOVES) syndrome
[29], in which bone overgrowthmay be the result of a paracrine signal-
ing defect involving VEGF. A similar mechanism may be at work in the
rare Proteus syndrome, caused by somatic mosaic mutations in RAC-
alpha serine/threonine protein kinase (AKT1), also an active participant
in VEGF signaling [30]. Other rare syndromes such as Sturge–Weber, the
result of pernicious mosaic gain-of-function mutations in guanine-
nucleotide-binding protein G(q) subunit alpha (GNAQ), substantiate a
possible defect in paracrine signaling from surrounding tissues [31].
In Gorham–Stout disease, characterized by massive osteolysis and
hemangiomatosis, VEGF secreted by osteoblasts may induce vasculariza-
tion,while absence of nuclear VEGFmost likely affects osteoblast differen-
tiation [32]. Recent data demonstrated the role of tumor endothelial
marker 8 (TEM8) in the pathophysiology of hemangiomas [33] and
growth retardation, alopecia, pseudoanodontia, and optic atrophy
(GAPO) syndrome [34] through regulation of VEGF signaling in endothe-
lial cells. TEM8 forms a complex with VEGFR2 in endothelial cells and in-
hibits transcription of VEGFR1, thus protecting the cells from excessive
signaling. In hemangiomas, the TEM8 complex becomes inactive, leading
to hyperactive VEGF-dependent VEGFR2 signaling.
As expected, the dynamic bone–blood tissue boundary is paramount
in the growth of skeletal elements. Pathologies disrupting this boundary
reﬂect the cross-talk in signaling pathways essential for cellular differ-
entiation and maintenance processes in the vascular and skeletal
systems. Further dissection of the geneticmechanisms behind these dis-
eases is warranted in order to identify new players in the maintenance
of vascular, skeletal, and ECM homeostasis.
Matrix — Lee
The primary structural component of the ECM, type I collagen, has
long been implicated in OI. Mutations in the alpha 1 chain of type I col-
lagen, themost common cause of OI, lead to low bonemass, bone fragil-
ity and deformities, and increased risk of fractures [35]. The ability of
bone to resist fractures depends on the intrinsic properties of the mate-
rials that form the bone matrix, the amount of bone (i.e. mass), and the
spatial distribution of the bone mass (i.e. microarchitecture). Type I
collagenopathies ﬁrst hinted toward defects beyond alterations in the
structure of the ECM and prompted evaluation of bone properties
at the organ, tissue, material, and molecular levels. Recessive forms
of OI comprise defects in enzymes responsible for collagen post-
translational modiﬁcations, such as the prolyl 3-hydroxylase-1 (P3H1)complex, as well as in collagen chaperones, which recruit other modify-
ing proteins [35]. Homozygous P3h1 null mice show overall decreased
bone density, delayed ossiﬁcation, and defects in collagen-rich tissues
such as tendons and skin [36]. However, mice harboring a mutation
that abolishes the hydroxylase activity of P3H1 (H662A) show
decreased trabecular bone mass and abnormal collagen ﬁbers, but no
generalized defects in connective tissue. Despite the abrogation of enzy-
matic function in this mousemodel, the stability of the P3H1 complex is
maintained and no post-translational over-modiﬁcation of other amino
acid residues occurs, enabling normal assembly and folding of the colla-
gen ﬁbers [37]. As in the P3h1 knockout mouse, complete ablation of
cartilage-associated protein (CRTAP), a component of the P3H1 enzy-
matic complex, affects collagen ﬁbril assembly and collagen–protein in-
teractions, important for matrix–cell signaling [38]. Crtap null mice
show increased TGF-β signaling, also observed in the dominant form
of OI due to the G610C mutation found in a large Amish kindred,
owing to changes in binding of the proteoglycan decorin to type I colla-
gen,which disrupt TGF-β binding to collagen ﬁbers and protein–protein
interactions [39]. Overall, animal studies combined with genetic analy-
sis of human OI mutations conﬁrm that alterations in the biochemistry
of collagen proteins can signiﬁcantly affect folding and intracellular
trafﬁcking through the endoplasmic reticulum (ER) and the Golgi appa-
ratus. These altered structural and distribution patterns, together with
defects in collagen extracellular ﬁber assembly and cross-linking, result
in defective matrix–bone cell communication.
The underlying deﬁciencies in OI are notmerely structural; disruption
of the collagenous reticulate can negatively affect cell signalingwithin the
matrix, with profound effects in bone architecture and strength. In the
future, additional signaling pathways affected in collagenopathies will
certainly be identiﬁed, and the relative contributions of normal homeo-
static responses such as ER stress will be determined. Themain challenge
consists in modeling all the pathophysiological components of these
diseases in order to target them in an optimal way and personalize
treatment.
The transcriptional landscape in the skeleton—McMahon
Dr. AndrewMcMahon described experiments inwhich DNA bound to
the chondrocyte transcription factor SOX9 or the osteoblast transcription
factor OSX was immunoprecipitated from genetically engineered mice,
massively parallel-sequenced, and compared to massively parallel
mRNA sequence in order to understand how these transcription factors
coordinately regulate gene expression in cells.
Defects in cellular differentiation programs and the signaling path-
ways that govern them during endochondral ossiﬁcation undeniably
compromise skeletal development. At the intracellular level, the balance
between proliferation and differentiation requires the concerted action
of master regulatory signals at different steps. While RUNX2 is essential
to determine the fate of osteoblasts early on in the differentiation
process, it also switches chondrocyte proliferation into hypertrophic
differentiation at a later stage. SOX9 and other members of the SOX
family of transcription factors are essential for chondrocyte speciﬁcation
and differentiation [40]. SOX9 haploinsufﬁciency causes campomelic
dysplasia [2], and differing degrees of severity in skeletalmalformations
in animal models, ranging from complete absence of ossiﬁcation to im-
paired chondrocyte differentiation, according to the stage of develop-
ment of SOX9 removal [41]. Transcriptional proﬁling of a neonatal
chondrocytic sample obtained from mouse ribs revealed that this tran-
scription factor acts as a focal point in the gene regulatory network of
the cell, binding to about 27,500 regions in the genome. SOX9 is usually
associated with highly conserved regions corresponding to regulatory
regions, namely promoters, but is also active in sites distant from the
transcription start. In theﬁrst case, SOX9 engagement is not through en-
richment of bona ﬁde SOX9-binding sites; association to these regions
correlates with the strength of transcription of housekeeping genes
without a strong chondrogenic signature. In the second type of
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ments. These super enhancer regions are ﬂanked by acetylated nu-
cleosomes, a hallmark of open chromatin, and transcriptional
coactivators such as p300 to regulate cartilage- and chondrocyte-
speciﬁc genes.
Despite the pivotal action of SOX9 at promoter and other regulatory
sites, other factors engage with the transcription factor and affect its
transcriptional program.Motifs for activation protein 1 (AP-1) are high-
ly enriched in SOX9-recovered regions, and the distribution of c-Jun, an
AP-1 subunit, clearly overlapswith that of SOX9 around the gene for col-
lagen type II (Col2a1). In vitro studies suggest that c-Jun interacts with
SOX9 at chondrocyte enhancers, possibly inhibiting one another, but
its role in chondrogenesis is currently unknown. Therefore, subtle
changes in levels of SOX9 may have important implications in the
context of rare genetic diseases in which there is overexpression of
this transcription factor.
Similar procedures applied to calvarial samples showed the pres-
ence of about 2,000 binding sites for OSX (Sp7), predominantly located
more than 10 kb away from the transcription start site. As expected,
these OSX-binding motifs were recovered near genes that have previ-
ously been implicated in skeletogenesis and ossiﬁcation. OSX binds
AT-rich regions within these motifs through partners such as DLX5,
which is capable of binding to a novel enhancer at the Notch2 locus, a
known inhibitor of osteoblast differentiation [42].
The coordinated activation/inactivation of genes involved in chon-
drocyte and osteoblast differentiation and proliferation ensures the
continuous elongation of the growth plate. These complex regulatory
networks are expected to undergo dynamic changes during bone re-
modeling and development and may be involved in bone disease
through (de)stabilization of interactions and (in)activation of speciﬁc
DNA binding sites.
How rare bone diseases inform the search for agents to improve
skeletal health
Drs. Graham Russell, Michael Whyte, Matthew Warman, Denise
Adams, and Laurence Legeai-Mallet provided examples of rare bone
diseases that suggested new strategies for improving skeletal health,
or provided animal models or patient populations for which initial
proof of principle validations could be performed.
Treating osteoclastic overactivity — Russell
The use of drugs that inhibit bone resorption (‘anti-resorptives’)
dominates the therapy of bone diseases, many of which are character-
ized by enhanced bone destruction. These disorders includemany com-
mon diseases such as osteoporosis, PDB,myeloma, and bonemetastases
secondary to breast, prostate and other cancers, but also many less
common acquired or inherited diseases such as OI.
The term ‘anti-resorptive’ is used to refer to drugs that inhibit bone
resorption, usually via direct or indirect actions on osteoclast develop-
ment and activity; alternative terms such as ‘anti-catabolic’ are some-
times used to contrast with ‘anabolic’ agents that stimulate bone
formation. For osteoporosis, treatments have historically included
hormones such as estrogens as well as calcitonins, which have been
replaced by more effective treatments. Selective Estrogen Receptor
Modulators (SERMs) display the beneﬁts of estrogens without all their
adverse effects and offered much promise, but many failed during
clinical development. Raloxifene and bazedoxifene are SERMs that
continue to be used in selected patients. Currently, the mainstay of
treatment worldwide is still with bisphosphonates, which have been
used clinically for more than 40 years, and which can reduce fracture
occurrence at vertebral and non-vertebral sites, including the hips.
The most recently introduced new drug is the anti-RANKL antibody
denosumab, also effective against these fractures. Several cathepsin K
inhibitors have also been studied, but among these only odanacatib isclose to being registered for clinical use. Strontium salts (e.g. ranelate)
have been introduced for treating osteoporosis in somebut not all coun-
tries, but their mode of action remains unclear [43].
It is fascinating to note how the study of rare diseases has led to
many of the drugs now used or being developed for the treatment of
skeletal diseases. Even bisphosphonates, as stable chemical analogs of
inorganic pyrophosphate (PPi), can be traced back to studies on the
inherited disorder hypophosphatasia (HPP). In HPP, the enzyme alka-
line phosphatase (ALP) is deﬁcient, and the resulting increased levels
of PPi, the body's natural water softener, contribute to the defective
skeletal mineralization. Altered pyrophosphate metabolism also occurs
in other calciﬁcation disorders, such as chondrocalcinosis and infantile
vascular calciﬁcation.
Bisphosphonates were ﬁrst studied for their inhibitory effects on
mineralization. Only when it was realized that they could also affect
mineral dissolution were their effects on bone resorption evaluated.
The development of both denosumab and cathepsin K inhibitors
can also be traced back to the study of rare diseases of bone. Among
other potential anti-resorptives derived from studies of various
osteopetrotic disorders are Src inhibitors, chloride channel blockers,
and adenosine triphosphate (ATP) proton pump inhibitors, but to date
only denosumab has been registered for clinical use. It is evident that
the pharmacological basis for the action of each of these agents is differ-
ent, and these properties need to be considered when determining the
optimal ways they can be used in clinical practice.
At the cellular level, bisphosphonates impair osteoclast activity via
inhibition of farnesyl pyrophosphate synthase, which is involved in
the prenylation of proteins required for the formation, function and
survival of osteoclasts (e.g. Ras and Rho) [44]. Denosumab is effective
in the prevention of fractures of the hip and spine, but shows differences
in duration of action [45].While the effects of zoledronate stabilize after
three years of use [46], denosumab induces sustained increases in
bonemass, even after six years [47]; however, biomarkers of bone turn-
over increase rapidly following discontinuation of treatment with
denosumab while they are sustained after three years of interruption
of zoledronate [48]. Moreover, several studies in patients with different
types of cancer showed that denosumab is more effective than
zoledronate in delaying the onset of ﬁrst skeletal-related events [49,50].
Owing to their involvement in the mevalonate pathway,
bisphosphonates may also have beneﬁcial effects in other non-skeletal
systems. Studies in humans and animal models suggest a positive effect
on lifespan [51]. Moreover, alendronate reduces the risk of myocardial
infarction in patients with rheumatoid arthritis [52], and zoledronate
in combination with statins increases the lifespan of a mouse model of
Hutchinson–Gilford progeria syndrome [53]. Bisphosphonates have an
excellent safety proﬁle, and new and even more potent compounds
with lower bone afﬁnity are under development for these novel
applications.
Targeting enzymes and other proteins to bone —Whyte
The osteoblast/osteoclast dyad is not the only culprit in low bone
mineral density, which can in fact result from defective skeletal bone
mineralization in diseases such as HPP. The biochemical hallmark of
the disease is low serum ALP activity [54]. In HPP, the tissue non-
speciﬁc isoenzyme of ALP (TNSALP) is hypo-active [2]. TNSALP is a
cell-surface enzyme expressed especially in the liver, bone, and kidney
and plays a role in skeletalmineralization by regulating the extracellular
level of PPi, a potent inhibitor ofmineralization and themain pathological
driver in HPP. Vesicles in the skeletal matrix rupture, releasing hydroxy-
apatite, but excessive PPi blocks the growth of these crystals for deposi-
tion into bone. Phosphoethanolamine (PEA) and pyridoxal 5′-phosphate
(PLP) are additional natural substrates for the isoenzyme [55].
A total of 275 mutations in TNSALP have been identiﬁed in HPP
across a wide spectrum of symptom severity [56]. The most severe
form of the disease leads to extreme hypomineralization at birth, and
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patients appear normal at birth but develop rickets before six months-
of-age, and respiratory failure with a fatal outcome occurs in approxi-
mately 50% of cases. During childhood, HPP can manifest as rickets
with short stature, tooth loss, and craniosynostosis, whereas adults
with HPP can present with metatarsal stress fractures, femoral
pseudo-fractures, chondrocalcinosis, and PPi arthropathy. The mildest
form of the disease (‘odonto’) is characterized by premature tooth loss
with no radiological or skeletal abnormalities [55]. The disease remains
without a medical treatment.
Initial studies showed that infusions of ALP-rich plasma obtained from
patients with PDB and administered intravenously did not signiﬁcantly
improve clinical or radiographic ﬁndings in infantile HPP [57]. However,
bone marrow cell transplantation and implantation of bone fragments
and cultured osteoblasts improved the rickets [58,59]. Teriparatide, a re-
combinant form of parathyroid hormone (PTH) and PTH itself have
been administered off-label to adults with HPP with the goal of stimulat-
ing TNSALP production in osteoblasts [60]. The partial success of these ap-
proaches led to the search for new bone-targeted therapies such as
directed enzyme replacement therapy (ERT). Asfotase alfa is a recombi-
nant protein that comprises the TNSALP homodimer and a terminal
deca-aspartate motif responsible for targeting this biologic to mineral.
Asfotase alfa rescues the metabolic and skeletal defects in the Akp2 null
mouse, which recapitulates infantile HPP, including the dental abnormal-
ities [61,62]. In an ongoing phase II extension study of life-threatening
perinatal and infantile HPP, experimental asfotase alfa induced sustained
improvements in bonemineralization andpulmonary and cognitive func-
tion. In these patients, changes in the radiographic features of severe HPP
were observed as early as threemonths, with signiﬁcant improvement in
rickets and survival at one year. This agent may potentially be used in
other conditions leading to abnormal accumulation of PPi levels, such as
neuroﬁbromatosis type-1. Overall, asfotase alfa showed a favorable toler-
ability proﬁle, supporting the use of tissue-directed ERT in the treatment
of mineralization defects.
Antibody-based modulation of extracellular signaling —Warman
Since Jenner scientiﬁcally demonstrated that cowpox inoculation
could lessen disease severity caused by smallpox, germinal discoveries
in the ﬁelds of immunology, cell biology, andmolecular biology are cul-
minating in an unprecedented ability to produce humanized monoclo-
nal antibodies (mAbs) that have potent, sensitive, and selective
biologic effects. The strategy of using mAbs targeting sclerostin, a Wnt
signaling antagonist, to improve bone mass and strength has its origins
in the study of four rare skeletal diseases: sclerosteosis and van Buchem
disease, which are caused by mutations affecting SOST [63], and
osteoporosis-pseudoglioma syndrome (OPPG) and dominant high
bone mass (HBM) syndrome, which are caused by mutations affecting
the Wnt co-receptor low-density lipoprotein receptor-related protein
5 (LRP5) [64–66].
Studies with cultured cells and genetically modiﬁed mice suggest
that sclerostin deﬁciency and LRP5 HBM mutations enhance Wnt
signaling in the bone [67,68]. Although patients lacking sclerostin or
having LRP5 HBM-causing mutations can develop complications from
excessive bone formation [69]; importantly, these patients do not ap-
pear to be at increased risk for non-skeletal complications of deranged
Wnt signaling, such as neoplasia and cognitive impairment. Therefore,
mAbs that neutralize sclerostin activity have been developed with the
goal of selectively enhancing Wnt signaling in the bone to increase
bone formation [70].
Animalmodels of human rare disease phenotypes have been studied
to support the use of antibodies to target Wnt signaling with the objec-
tive of increasing bonemass and strength. Amousemodel harboring the
missense mutation responsible for HBM recapitulates the human
phenotype [71] and induces LRP5 resistance to the inhibitory effects of
sclerostin on bone formation [68]. Therapies that employ mAb-mediated sclerostin inhibition in human populations are currently in
phases II and III clinical trials for patients with common forms of low
bone mass and strength (www.clinicaltrials.gov). However, these
same therapies may beneﬁt patients with rare skeletal fragility syn-
dromes as well. For example, sclerostin depletion improved skeletal
properties in Lrp5 null mouse models of human OPPG [72,73]. More-
over, the beneﬁt of enhancing Wnt signaling in patients with OI is
being tested in mouse models for mild, moderate, and severe OI
by crossing OI mice with Lrp5 HBM mice [74], and by administering
anti-sclerostin neutralizing antibodies to OI mice [74–77]. Mice with a
Col1a2G610C OI mutation and an Lrp5 HBM-causing allele had increased
bone mass and strength relative to mice with OI alone, as did Col1aG610C
OI mice and Brtlmice that received anti-sclerostin antibodies [74,76,77],
although not the more severe Jrt model of OI [75]. Therapeutic mAbs
targeting other biologically active proteins in bone may also beneﬁt
patients with OI. Anti-TGFß antibodies have recently been shown to
improve bone mass and strength in the Col1a2G610C knockin and Crtap
null models of human OI [39].
In summary, the study of rare diseases sharing defects in key mem-
bers of the Wnt signaling has deﬁnitely helped unravel the role of this
pathway in the process of bone formation, pointing to the feasibility of
using inhibitory antibodies in the treatment of rare bone diseases. It is
likely that other human skeletal disease phenotypes caused by loss-of-
function or gain-of-function mutations in secreted or outer cell mem-
brane proteins will provide new targets for therapeutic antibodies that
can enhance bone health.
Inhibition of intracellular signaling by small molecules — Adams
The mammalian target of rapamycin (mTOR)/PI3K/AKT signaling
pathway regulates cell growth, proliferation, and survival, and interacts
with several other pathways, including the angiogenic HIF pathway
[78]. Consequentially, small molecule inhibitors of mTOR/PI3K/AKT
signaling constitute promising agents in the treatment of cancer and
vascular anomalies. Several case studies report the successful use
of sirolimus, an mTOR inhibitor, in the treatment of kaposiform
hemangioendothelioma (KHE), a low-malignancy tumor with a lym-
phatic component, without signiﬁcant side effects [79,80]. Preliminary
data from an ongoing open-label, phase II trial (NCT00975819)
conducted in children and young adults with complicated vascular
anomalies showed the efﬁcacy of sirolimus in speciﬁc subgroups of pa-
tients, with an overall partial response of approximately 85% after one
year. Remarkably, quality of life, also a primary outcome measure of
the trial, improved signiﬁcantly or remained stable with treatment
with sirolimus. In this trial, mucositis was themost frequent side effect,
and increased risk for interstitial disease was observed, as well as pul-
monary, metabolic, and immune adverse events. The long-term effects
of sirolimus are unknown, and low doses are currently being used to
prevent complications. mTOR inhibitors also show anti-tumor activity
and acceptable tolerability in mouse models predisposed to cancer,
but have produced somewhat poor outcomes in clinical trials as mono-
therapy, with the exception of renal cell carcinoma [78]. Dual mTOR/
PI3K agents are currently being tested in combination with cytotoxic
therapy to improve efﬁcacy and reduce the possibility of acquired
drug resistance.
In the context of bone pathologies, animal studies showed that
inhibition of the mTOR pathway decreases bone resorption through
interference with the RANKL/RANK/OPG system. The mTOR inhibitor
everolimus inhibited the proliferation of osteosarcoma-derived
cells and improved tumor response when used in combination
with zoledronate, an approach that may overcome development of re-
sistance to the small molecule [81]. The phase III BOLERO-2 study
(NCT00863655) evaluated a combination of everolimus and an aroma-
tase inhibitor (exemestane) in postmenopausal womenwithmetastatic
breast cancer; signiﬁcant survival beneﬁts were observed, with reduced
bone resorption and incidence of malignant progression in bone.
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of vascular and oncologic disease and their complications paved the
way to new therapeutic applications for dual small molecule inhibitors
of mTOR/PI3K. Ongoing studies are comparing chemotherapy with vin-
cristinewith sirolimus in KHE and investigating the potential additional
beneﬁts of combining sirolimus with bisphosphonates in bone cancer
settings. Unfortunately not much is known about the effects of these
small molecules in patients with both bone and vascular abnormalities,
such as Gorham-Stout and Generalized Lymphatic Anomaly, and the
next few years will certainly reveal new treatment approaches.
Use of synthetic polypeptides to promote skeletal growth — Legeai-Mallet
Peptides have been successfully used in the treatment of several dis-
eases, insulin being one of the ﬁrst notable synthetic polypeptides used
in therapy. Several peptide therapeutics are now under development or
available for indications as diverse as prostate cancer, diabetes, and
Cushing disease, but they present limitations, such as susceptibility to
enzymatic degradation, immunogenicity, and the possibility of aggrega-
tion, adsorption, and denaturation once inside the cells. Bone-related
disorders have also been targeted with synthetic peptides, in particular
acromegaly, short stature, osteoarthritis, and osteoporosis. Recombi-
nant insulin-like growth factor-1 (mecasermin) is now available in the
US and EU for the treatment of patients with growth failure due to in-
sensitivity to growth hormone (GH) [82]. Another synthetic peptide,
teriparatide, increases bone formation and is also chondroprotective
[83,84]; intermittent teriparatide administration rescues the abnormal
skeletal development in a mouse model of achondroplasia [85], the
most common form of dwarﬁsm. GH is minimally effective for the
treatment of achondroplasia, and current management of the disease
involves surgical limb lengthening, which is associated with high risk
of infection and joint and soft tissue damage [86]. Activating mutations
in the FGF Receptor 3 (FGFR3) cause achondroplasia by dysregulating
downstream pathways, such as mitogen-activated protein kinases
(MAPKs) [87].
The importance of C-type natriuretic peptide (CNP) and its receptor,
natriuretic peptide receptor 2 (NPR2), for endochondral skeletal growth
was suggested bymice overexpressing brain natriuretic peptide [88], or
mice with loss-of-function mutations in Cnp [89], and in humans who
have acromesomelic dysplasia, type Maroteaux [90], due to loss of
NPR2 or skeletal overgrowth due to with chromosomal translocations
involving CNP [91]. Transgene-mediated overexpression of CNP im-
proved the skeletal phenotype in an achondroplasia mouse model
[92]. A new CNP analog, designated BMN-111, is currently being inves-
tigated for the treatment of achondroplasia. CNP, a 22-amino acid pep-
tide, has a short half-life due to neutral endopeptidase degradation, but
its analog under development shows similar selectivity and potency and
is resistant to enzymatic proteolytic activity. The peptide is a known
negative regulator of FGFR3, and its administration improves the pheno-
type in a mousemodel of achondroplasia in a MAPK-dependent manner
[93]. In a six-month study of wild-type cynomolgus monkeys, BMN-111
increased tibial length and growth rate and did not raise safety concerns.
In cultures of primary chondrocytes obtained from patients, BMN-111
abrogates the constitutive activation of FGFR3 through inhibition of
ERK1/2 phosphorylation. Ex vivo, the peptide promotes proliferation
and differentiation of murine chondrocytes heterozygous for the Fgfr3
Y367C mutation and rescues the size and architecture of the growth
plate in embryonic femur cultures. Daily sub-cutaneous injections of
BMN-111 for 20 days resulted in signiﬁcant increases in the growth of
the axial and appendicular skeleton in the Fgfr3Y367C/+ mouse model
mimicking achondroplasia [93]. A phase I study (NCT01590446) in
healthy volunteers was completed in 2012, and phase II evaluation is
underway in patients 5–14 years old (NCT02055157). The objectives of
the trial are to evaluate the safety of BMN-111 and changes in absolute
growthparameters and in bodyproportions, aswell as functional aspects
of skeletal growth.The phase II trial of BMN-111 in children with achondroplasia will
explore whether the success obtained in preclinical animal studies can
be extended to humans. As in OI, it is important to assess not only the
‘quantity’ but also the ‘quality’ of the new extended bones, as
measured by several biomechanical parameters.
Conclusions
The new knowledgewe have gained frompatients with rare skeletal
diseases is enormous and impossible to summarize in a single article.
Using a tiny subset of examples, the speakers at the Rare Bone Disease
symposium conveyed the importance of learning from patients affected
with rare skeletal diseases. The study of these patients yield unexpected
insights about the normal physiology of the skeletal system and suggest
new targets and strategies for improving skeletal health.
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